United Therapeutics Corporation (UTHR) Q2 FY26 Earnings Call

Near-term execution weakened, but record patient metrics and potential 2027 launches support a stronger second half and longer-term growth.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-05
Length31 minutes
EPS$7.27
EPS consensus$6.82
Revenue$783.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25 · Q2 FY25

All UTHR earnings · Back to UTHR overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.